These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 28706579)

  • 1. Conventional
    Song JE; Kim DY
    World J Hepatol; 2017 Jun; 9(18):808-814. PubMed ID: 28706579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma.
    Baur J; Ritter CO; Germer CT; Klein I; Kickuth R; Steger U
    Hepat Med; 2016; 8():69-74. PubMed ID: 27382341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Tang J; Huang Z; Xu J; Lv Q; Wang P
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
    Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.
    Facciorusso A
    World J Gastroenterol; 2018 Jan; 24(2):161-169. PubMed ID: 29375202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 9. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302.
    Ikeda M; Arai Y; Inaba Y; Tanaka T; Sugawara S; Kodama Y; Aramaki T; Anai H; Morita S; Tsukahara Y; Seki H; Sato M; Kamimura K; Azama K; Tsurusaki M; Sugihara E; Miyazaki M; Kobayashi T; Sone M
    Liver Cancer; 2022 Sep; 11(5):440-450. PubMed ID: 36158586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres
    Ma Y; Zhao C; Zhao H; Li H; Chen C; Xiang H; Zheng C; Ma C; Luo C; Qiu H; Yao Y; Hu H; Xiong B; Zhou J; Zhu H; Long Q
    Am J Transl Res; 2019; 11(12):7456-7470. PubMed ID: 31934293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
    Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
    World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.
    Li H; Liang C; Kuang D; Huang G; Zhang M; Chen P; Zheng Q; Xu W; Ren J; Han X; Duan X
    Cancer Biol Ther; 2023 Dec; 24(1):2166335. PubMed ID: 36751709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.
    Lee YK; Jung KS; Kim DY; Choi JY; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim GM; Kim MD; Park SI; Won JY; Lee DY
    J Gastroenterol Hepatol; 2017 Feb; 32(2):487-496. PubMed ID: 27503585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma.
    Razi M; Safiullah S; Gu J; He X; Razi M; Kong J
    J Interv Med; 2022 Feb; 5(1):10-14. PubMed ID: 35586278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma.
    Chen S; Yu W; Zhang K; Liu W; Chen C
    Hepatol Res; 2021 Apr; 51(4):482-489. PubMed ID: 33462925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
    Wen P; Chen SD; Wang JR; Zeng YH
    Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
    Adel H; Shazlee MK; Qamar S; Hyder SMS; Razaque A
    Cureus; 2023 Jul; 15(7):e41701. PubMed ID: 37575777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.